On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize IBD as a heterogeneous group of idiopathic inflammatory conditions, primarily and , driven by a complex interplay of genetic susceptibility, environmental triggers, and dysregulated immune responses. While CD is characterized by 'skip lesions' and transmural involvement, UC typically presents with continuous mucosal inflammation starting from the rectum.
- •Identify the global epidemiological shift where IBD prevalence is increasing worldwide, now affecting over 5 million individuals with UC alone. While traditionally a disease of young adults, the 'elderly-onset' population (≥60 years) is the fastest-growing demographic, presenting unique challenges due to comorbidities and increased frailty.
- •Understand the systemic nature of IBD, which extends beyond the gut to include extraintestinal manifestations (EIMs) such as , uveitis, and primary sclerosing cholangitis. IBD is also associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and venous thromboembolism (VTE), particularly during active flares.
- •Note the importance of phenotypic variants such as perianal fistulizing Crohn's disease (pfCD) and acute severe ulcerative colitis (ASUC). ASUC is a life-threatening emergency requiring rapid hospitalization and intensive medical rescue to avoid emergency colectomy.
- •Consider the role of genetic drivers like the NOD2 gene, which is found in approximately 40% of Caucasian CD patients and is linked to related multisystem disorders such as Yao syndrome (YAOS) and Blau syndrome.
Evaluation
- •Suspect IBD in patients presenting with chronic diarrhea (especially nocturnal), hematochezia, abdominal pain, weight loss, or unexplained growth failure in pediatric populations. Always ask about a family history of IBD and the presence of extraintestinal symptoms like joint pain or skin rashes.
- •Obtain baseline inflammatory biomarkers, specifically C-reactive protein (CRP) and fecal calprotectin. Fecal calprotectin is highly sensitive for intestinal inflammation and is used to differentiate IBD from functional disorders like (IBS).
- •Order a complete blood count (CBC) and iron studies to screen for anemia, which is the most common systemic complication. Also, check albumin levels as hypoalbuminemia can indicate severe disease and predict poor response to certain biologics like infliximab.
- •Perform a thorough physical examination, including a digital rectal exam and inspection of the perianal area for skin tags, fistulas, or abscesses, which are highly suggestive of Crohn's disease.
- •Utilize (IUS) as a first-line, non-invasive tool to assess bowel wall thickness (BWT). A BWT > 3 mm is a key indicator of active inflammation and can be used for longitudinal monitoring without radiation exposure.
- •Order Magnetic Resonance Enterography (MRE) or CT Enterography (CTE) to evaluate for small bowel involvement, strictures, or penetrating disease (fistulas/abscesses) that cannot be reached by standard endoscopy.
- •Perform a with multiple biopsies from both inflamed and non-inflamed segments. Histological features such as crypt abscesses in UC or non-caseating granulomas in CD are diagnostic hallmarks.
- •Classify the disease using the Montreal Classification for adults or the Paris Classification for pediatric patients to standardize the description of disease location, behavior, and age at onset.
- •Rule out infectious mimics, particularly Clostridioides difficile, which has a high prevalence (up to 28%) in IBD patients on biologics and can trigger or exacerbate flares.
- •Screen for baseline sarcopenia and nutritional deficiencies using EWGSOP2 criteria, as muscle loss is a significant predictor of poor outcomes and incident IBD.
- •Evaluate for perianal disease using pelvic MRI, which is the reference standard for classifying complex branching fistulas, or transperineal ultrasonography (TPUS) as a non-invasive alternative.
- •Assess for psychological comorbidities, including anxiety and depression, which are highly prevalent and closely correlated with disease activity, especially in adolescents.
Management
- •Adopt a 'treat-to-target' strategy aiming for transmural healing (TMH), defined by the normalization of bowel wall thickness on ultrasound, rather than just symptomatic relief. TMH is associated with superior long-term outcomes and lower surgery rates.
- •Induce remission in moderate-to-severe UC using Guselkumab 200 mg or 400 mg IV at weeks 0, 4, and 8, or initiate anti-TNF therapy such as Infliximab 5 mg/kg IV.
- •Manage Acute Severe Ulcerative Colitis (ASUC) with inpatient IV Methylprednisolone 60 mg/day. If no response is seen by day 3 (e.g., PUCAI score > 45 in children), initiate rescue therapy with Infliximab 5 mg/kg or Cyclosporine.
- •Utilize personalized dosing models (e.g., iDose) for Infliximab in ASUC to account for high drug clearance in patients with high inflammatory burdens, aiming to maximize colectomy-free survival.
- •Administer Exclusive Enteral Nutrition (EEN) as first-line induction therapy for pediatric Crohn's disease. Provide 100% of daily caloric requirements via liquid formula for 6 to 8 weeks to induce mucosal healing and avoid steroid toxicity.
- •Transition to maintenance therapy with Subcutaneous (SC) Infliximab 120 mg every 2 weeks, which often achieves higher colonic tissue concentrations than IV administration.
- •Consider Ustekinumab for Crohn's disease, induced with a weight-tiered IV dose (e.g., 6 mg/kg for patients ≥40 kg) and maintained with 90 mg SC every 8 weeks, especially in patients with symptomatic ileal strictures.
- •Employ small molecule JAK inhibitors like Upadacitinib 15-30 mg daily or Filgotinib 200 mg daily for refractory UC cases that have failed biologic therapy.
- •Monitor therapy using Therapeutic Drug Monitoring (TDM) to assess drug trough levels and the development of anti-drug antibodies (ADAs), particularly when clinical response is lost.
- •Address iron deficiency anemia with IV Iron (e.g., Ferric Carboxymaltose 1000 mg) rather than oral iron during active flares to ensure better absorption and avoid GI irritation.
- •Implement bone protection for patients on prolonged corticosteroids, including Calcium 1000–1200 mg/day and Vitamin D 800–1000 IU/day, to mitigate the risk of osteoporosis and fractures.
- •Refer for surgical consultation early in cases of uncomplicated ileocaecal CD; laparoscopic ileocaecal resection is a valid alternative to Infliximab with high rates of long-term therapy-free remission.
- •Manage fibrostenotic strictures with Endoscopic Balloon Dilation (EBD) or Endoscopic Stricturotomy (ESt) for short (< 5 cm) accessible lesions before considering surgical resection.
- •Maintain maintenance therapy throughout pregnancy to prevent flares, as active disease is the greatest risk to the fetus. Anti-TNFs, Vedolizumab, and Ustekinumab are generally considered safe during gestation.
- •Avoid live vaccines in patients on biologics or immunosuppressants. Ensure all age-appropriate vaccinations and screenings (e.g., TB, Hepatitis B/C) are completed prior to starting advanced therapies.
Board Review — High Yield
- •ASCA vs pANCA — Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with Crohn's; pANCA is more common in Ulcerative Colitis.
- •Transmural vs Mucosal — Crohn's involves the full thickness of the bowel wall (transmural); UC is limited to the mucosa and submucosa.
- •Skip Lesions — Characteristic of Crohn's disease, where areas of inflammation are separated by normal-appearing mucosa.
- •Crypt Abscesses — A classic histological finding in Ulcerative Colitis representing neutrophils within the colonic crypts.
- •Toxic Megacolon — A surgical emergency defined by colonic dilation > 6 cm associated with systemic toxicity.
- •Exclusive Enteral Nutrition (EEN) — The preferred first-line induction therapy for pediatric Crohn's disease, superior to steroids for mucosal healing.
- •Rutgeerts Score — Used to assess the risk of endoscopic recurrence in Crohn's disease after ileocaecal resection.
- •NOD2/CARD15 — The first gene associated with Crohn's disease susceptibility, particularly ileal involvement.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸IBD is a systemic inflammatory condition, not just a localized GI disorder, and is associated with accelerated gut aging and increased cardiovascular risk [12, 13].
- ▸Crohn's disease is defined by transmural inflammation and potential involvement of the entire GI tract, whereas ulcerative colitis is restricted to mucosal inflammation of the colon [1, 8].
- ▸NOD2 variants are present in 40% of Caucasian CD patients and link IBD to other multisystem inflammatory disorders like Yao syndrome [10].
Definition and Synonyms
Inflammatory Bowel Disease (IBD) is a group of chronic, relapsing, immune-mediated systemic inflammatory disorders characterized by persistent immune activation and cyclical tissue damage within the tract [8]D[12]D[13]D[18]D. The condition is primarily driven by mucosal inflammation, epithelial injury, and transmural involvement, resulting in a highly heterogeneous clinical presentation [1][8]D.
Also Called: Idiopathic inflammatory bowel disease, chronic inflammatory enteropathy [3], and sometimes referred to by its primary subtypes, (CD) and (UC).
Key Definitions of Phases and Stages
Understanding the temporal and physiological progression of IBD is essential for clinical stratification. The disease course is typically characterized by the following phases:
- Active Disease (Flare): Periods of heightened inflammatory burden, often marked by clinical symptoms (e.g., diarrhea, hematochezia) and elevated biomarkers such as fecal calprotectin and C-reactive protein (CRP) [8]D[12]D[15]D.
- Remission: A state of clinical, endoscopic, or histologic quiescence where inflammatory activity is minimized.
- Nadir/Plateau: In the context of acute severe presentations, the point of maximal disease severity before response to rescue therapy or surgical intervention [19]D.
- Accelerated Gut Aging: A recently defined phenotype where even young IBD patients exhibit gut features akin to physiological aging, including impaired barrier function, cellular senescence, and intestinal frailty [13]D. Unlike physiological aging, which involves low-grade chronic inflammation, IBD-associated aging is driven by persistent immune activation and cyclical tissue damage [13]D.
Classification of Major Types
IBD is broadly classified into two main clinical entities, though significant overlap and unclassified cases exist. Classification is increasingly informed by molecular granularity, including single-cell RNA sequencing and spatial transcriptomics [1].
| Type | Key Distinguishing Feature | Associated Markers/Pathology |
|---|---|---|
| Crohn's Disease (CD) | Transmural inflammation; can involve any segment of the GI tract from mouth to anus [8]D. | ASCA (anti-Saccharomyces cerevisiae antibodies) [8]D[17]D; non-caseating granulomas. |
| Ulcerative Colitis (UC) | Mucosal inflammation and epithelial injury; limited to the colon and rectum [1]. | Continuous mucosal involvement; crypt abscesses [1]. |
| IBD-Unclassified (IBDU) | Features of both CD and UC that cannot be definitively categorized at diagnosis. | Often evolves into CD or UC over time. |
Phenotypic Variants and Related Syndromes
Beyond the broad categories of CD and UC, several specific variants and associated syndromes are recognized based on anatomical involvement, severity, or genetic drivers.
Perianal Fistulizing Crohn's Disease (pfCD)
This is a severe phenotype of CD characterized by the development of perianal fistulas and abscesses [2][9]D. These fistulas often arise near the anorectal junction and may extend beyond conventional classifications due to complex branching and high-origin involvement [9]D. Magnetic Resonance Imaging (MRI) is the reference standard for classification, though Transperineal Ultrasonography (TPUS) is an emerging non-invasive alternative [2][9]D.
Acute Severe Ulcerative Colitis (ASUC)
A life-threatening variant of UC requiring hospitalization and intensive medical [19]D. It is defined by high clinical activity scores and often requires rescue therapy with Infliximab 5 mg/kg or personalized dosing based on pharmacokinetic models to maximize colectomy-free survival [19]D.
NOD2-Related Disorders
Variants in the NOD2 gene are significant drivers of IBD, particularly in Caucasian populations where they are found in approximately 40% of CD patients [10]D. Related multisystem disorders include:
- Blau Syndrome: An autosomal dominant disease occurring primarily in children, caused by highly penetrant NOD2 variants [10]D.
- Yao Syndrome (YAOS): Characterized by recurrent fever, dermatitis, arthralgia, and distal limb edema, often possessing a specific constellation of NOD2 variants [10]D.
Systemic and Extraintestinal Manifestations
IBD is increasingly viewed as a systemic condition. It is associated with an increased risk of Atherosclerotic Cardiovascular Disease (ASCVD), particularly during periods of active flares [12]D. Furthermore, IBD may co-occur with other immune-mediated disorders such as Immunoglobulin A Vasculitis (IgAV), where medications like anti-TNF-α agents may influence the progression of both conditions [5].
Classification Systems for Disease Stratification
Clinicians utilize standardized systems to classify disease based on location and behavior, which informs prognosis and surgical planning.
- Montreal Classification: Categorizes CD by age at diagnosis (A1-A3), location (L1-L4, including upper GI involvement), and behavior (B1: non-stricturing, B2: stricturing, B3: penetrating) [8]D.
- Paris Classification: A pediatric-specific modification of the Montreal system that accounts for growth failure and more granular location data.
- NOVA Classification: Used to categorize dietary patterns, specifically the consumption of ultra-processed foods (UPF), which is increasingly linked to CD risk and outcomes [14].
| Biomarker | Utility in Classification | Clinical Reasoning |
|---|---|---|
| ASCA | High specificity for Crohn's Disease [8]D[17]D | Reflects immune reactivity to fungal antigens in the gut mycobiome [17]D. |
| Fecal Calprotectin | Monitoring disease activity and flares [8]D | Direct measure of intestinal neutrophilic inflammation. |
| LRG | Acute-phase reactant for CD and UC [15]D | Potentially more sensitive than CRP in patients on biologics as it is less IL-6 dependent [15]D. |
| CRP | General systemic inflammation marker [15]D | Responses may be attenuated in patients receiving biologic therapies [15]D. |
Epidemiology and Risk Factors
- ▸The global prevalence of Ulcerative Colitis is approximately **5 million**, with incidence rising most rapidly in newly industrialized regions [16, 45].
- ▸Novel environmental risk factors include outdoor artificial light at night (ALAN), poor oral health, and disrupted sleep patterns [31, 6, 29].
- ▸Pediatric IBD patients have a significantly increased risk of venous thromboembolism and psychological comorbidities like anxiety and depression [26, 24].
Inflammatory bowel disease (IBD), encompassing Ulcerative Colitis (UC) and (CD), has transitioned from a disease primarily affecting Western nations to a global health burden with a steadily increasing prevalence [43]D[47]D. The global prevalence of UC is currently estimated at approximately 5 million individuals, and both the incidence and prevalence of IBD are rising worldwide [16]D[45]D. This epidemiological shift is particularly evident in newly industrialized countries, where rapid urbanization and environmental changes have mirrored the historical trends seen in the West [41]D[42]D.
Demographic Distribution and Temporal Trends
IBD affects individuals across the lifespan, but recent data highlight specific shifts in demographic burden. While traditionally considered a disease of young adults, older adults (≥60 years) represent one of the fastest-growing age groups within the IBD population [28]. This demographic shift presents unique challenges, as older patients often present with higher rates of comorbidities and frailty, which are major drivers of adverse outcomes [36]D.
In the pediatric population, IBD is associated with significant morbidity beyond symptoms. Children and teenagers with IBD face an increased risk of Venous Thromboembolism (VTE) compared to their healthy peers [26]. Furthermore, psychological comorbidities are highly prevalent in this group; children and adolescents with IBD exhibit a high prevalence of anxiety and depression, which are closely associated with disease activity [24].
Environmental and Lifestyle Risk Factors
The rising global incidence of IBD is attributed to a complex interplay between genetic susceptibility and evolving environmental exposures [43]D. Recent large-scale prospective cohort studies have identified several novel risk factors:
- Artificial Light at Night (ALAN): Exposure to outdoor artificial light at night is significantly associated with a higher risk of developing UC, likely through disruption of circadian rhythms and immune modulation [31].
- Oral Health: Comprehensive oral health problems, including periodontal disease and tooth loss, are associated with an increased risk of incident IBD. This relationship may be mediated by systemic inflammatory responses and alterations in the oral-gut microbiome axis [6].
- Sleep Patterns: Poor sleep hygiene—defined by short duration (<7 hours/day), late chronotype, and frequent insomnia—is linked to a higher risk of bowel resection and all-cause mortality in patients with established IBD [29].
- Sarcopenia: The presence of sarcopenia (muscle loss) at baseline is a significant predictor of incident IBD. Probable sarcopenia and confirmed sarcopenia are both associated with an increased risk of developing the disease [33].
Comorbidities and Associated Risks
Patients with IBD are at an increased risk for various systemic complications and secondary conditions.
- Malignancy: Patients with CD have a heightened risk of intestinal malignancies, including Colorectal Cancer (CRC) and (SBC) [23]. The risk of colitis-associated colorectal cancer (CAC) is driven by chronic inflammation and complex interactions between the gut microbiota and immune cells like macrophages [39]D.
- Bone Health: IBD is a significant risk factor for all-cause and site-specific fractures, necessitating monitoring of bone mineral density [25].
- Autoimmune Associations: There is a significant comparative risk gradient among autoimmune diseases; for instance, patients with (AS) have a higher risk of developing IBD than those with psoriasis [46]D.
- Infections: IBD patients, particularly those on immunosuppressive or biologic therapy, are susceptible to opportunistic infections. The prevalence of Clostridioides difficile infection (CDI) in UC patients on biologics is approximately 28.2%, with independent risk factors including a modified Mayo score ≥11 and recent glucocorticoid use [35]D. Hepatitis E virus (HEV) is also an emerging concern in this population [27].
Pregnancy and Reproductive Health
Managing IBD during pregnancy requires careful risk stratification. The overall pooled prevalence of early pregnancy loss in women with IBD is 8.2% (95% CI, 6.2-10.8) [22]. While advanced therapies are increasingly used, safety data for newer agents like JAK inhibitors remain more limited compared to established anti-TNF therapies [22].
Protocol for Epidemiological Risk Stratification
Clinicians should follow a structured approach to identify high-risk patients at the time of diagnosis to mitigate long-term complications:
- Step 1: Nutritional and Musculoskeletal Assessment → Evaluate for baseline sarcopenia using EWGSOP2 criteria and screen for avoidant/restrictive food intake disorder (ARFID) risk, especially in pediatric-onset cases [33][32].
- Step 2: Environmental and Lifestyle Audit → Assess sleep quality, oral health status, and exposure to environmental triggers like artificial light at night [29][6][31].
- Step 3: Comorbidity and Infection Screening → Screen for comorbid ankylosing spondylitis and baseline infections (e.g., EBV-DNA, HEV) that may increase the risk of complications during therapy [46]D[35]D[27].
| Risk Factor | Association / Outcome | Evidence Level |
|---|---|---|
| Sarcopenia | Increased risk of incident IBD [33] | 2b |
| Ankylosing Spondylitis | Higher IBD risk compared to psoriasis [46]D | 5 |
| Poor Sleep Pattern | Increased risk of bowel resection and mortality [29] | 2b |
| Oral Health Problems | Associated with increased risk of incident IBD [6] | 2b |
| Outdoor Light (ALAN) | Higher risk of Ulcerative Colitis [31] | 2b |
| Pediatric Age | Increased risk of Venous Thromboembolism [26] | 2a |
| Mayo Score ≥11 | Independent risk factor for C. difficile in UC [35]D | 5 |
Management of Inflammatory Bowel Disease
- ▸Targeting transmural healing (TMH) via intestinal ultrasound is superior to targeting clinical symptoms alone for preventing long-term complications.
- ▸Subcutaneous Infliximab provides higher colonic tissue concentrations than IV administration and may overcome low-titer anti-drug antibodies.
- ▸Laparoscopic resection is a highly effective first-line alternative to biologics for localized, uncomplicated ileocaecal Crohn's disease.
The of Inflammatory Bowel Disease (IBD) has evolved from symptom-based control to a "treat-to-target" paradigm focusing on objective markers of inflammation. This approach aims to prevent structural bowel damage and reduce the long-term need for surgery [54]. Management strategies differ significantly between (CD) and (UC), though both rely on a tiered approach of induction and maintenance therapy using biologics and small molecules.
Step 1: Initial Assessment and Severity Classification
Clinicians must first classify disease activity to determine the appropriate setting for care. For UC, the modified Mayo score ≥11 or the presence of systemic symptoms (tachycardia, fever, anemia) indicates acute severe ulcerative colitis (ASUC), requiring immediate hospitalization [35]D[65]D. In pediatric patients, the presence of extraintestinal manifestations (EIMs) at diagnosis—found in 25% of CD and 14% of UC cases—is a strong predictor of a more severe disease course, including earlier steroid dependency and the need for biological therapy [58].
Initial assessment should include baseline biomarkers (CRP, fecal calprotectin) and, increasingly, (IUS). In pediatric CD, a bowel wall thickness (BWT) threshold measured via IUS can predict 1-year treatment response and remission [72]D. Patients with symptomatic ileal strictures or perianal abscesses require surgical consultation early in the assessment phase [56][67]D.
Step 2: Induction of Remission
Induction therapy aims to rapidly control inflammation. For moderate-to-severe UC, Guselkumab 200 mg or 400 mg IV at weeks 0, 4, and 8 has demonstrated significant molecular and cellular improvements in colonic tissue [49]. In ASUC, the standard of care remains IV corticosteroids (e.g., Methylprednisolone 60 mg/day); however, approximately 30-40% of patients fail to respond, necessitating rescue therapy [65]D.
Infliximab 5 mg/kg IV is the primary rescue agent for steroid-refractory ASUC. Because high inflammatory burden increases drug clearance, personalized dosing models (e.g., iDose) are used to adjust induction doses to maximize colectomy-free survival [19]D[55]. For pediatric CD, Ustekinumab is induced with a single weight-tiered IV dose (e.g., 6 mg/kg for those ≥40 kg) [50].
Step 3: Maintenance and Advanced Therapies
Once remission is achieved, therapy transitions to maintenance. Subcutaneous (SC) Infliximab (e.g., 120 mg every 2 weeks) is now preferred over IV administration in many cases because it achieves significantly higher colonic tissue drug concentrations [69]D. Interestingly, the development of anti-drug antibodies (ADAs) does not always correlate with clinical failure in SC Infliximab patients, suggesting that the higher trough levels may overcome low-titer immunogenicity [48].
For patients failing first-line biologics like , second-line options include switching to Infliximab or Ustekinumab 90 mg SC every 8 weeks [57]. In refractory UC, small molecule such as Upadacitinib 15 mg or 30 mg daily or Filgotinib 200 mg daily are effective [59]C[71]D. Filgotinib works by modulating the frequency and gene expression of circulating immune cell subsets, specifically targeting dysregulated T-cell populations [71]D.
Step 4: Monitoring and Titration to Target
Modern management targets transmural healing (TMH) rather than just mucosal healing. TMH, defined by the normalization of bowel wall thickness on ultrasound, is associated with a lower risk of long-term complications compared to clinical or endoscopic targets alone [54].
Monitoring should include:
- Therapeutic Drug Monitoring (TDM): Assessing drug clearance is vital, as high initial clearance of Infliximab is a major predictor of treatment failure and the development of ADAs [55].
- Non-invasive Imaging: IUS is a reliable tool for longitudinal monitoring, with early changes in BWT at week 4-8 predicting long-term remission [72]D.
- Biomarkers: Fecal aspirate transcriptomics is an emerging tool that may allow for the assessment of small bowel inflammation in asymptomatic CD patients without the need for full [70]D.
Step 5: Surgical Intervention and Long-term Outcomes
Surgery is not a failure of treatment but a strategic component of management. In uncomplicated ileocaecal CD, laparoscopic ileocaecal resection is a valid alternative to Infliximab, showing similar 10-year quality-of-life outcomes and high rates of long-term therapy-free remission [51]. For patients with ileal strictures, Ustekinumab may reduce the need for endoscopic balloon dilation (EBD) or surgery, though 25% of patients with symptomatic strictures will still require surgical intervention within one year [56].
In pregnant patients, advanced therapies (Anti-TNFs, Vedolizumab, Ustekinumab) are generally considered safe, with pooled prevalence rates for early pregnancy loss (8.2%) and congenital malformations (1.9%) being comparable to the general IBD population [22]. However, the method of delivery (Cesarean vs. vaginal) does not significantly impact the risk of severe maternal morbidity in IBD patients [66]D.
| Drug | Class | Dose (Maintenance) | Route | Key Consideration | Evidence Level |
|---|---|---|---|---|---|
| Infliximab | Anti-TNF | 120 mg every 2 weeks | SC | Higher tissue levels than IV [69]D | 1b |
| Ustekinumab | Anti-IL12/23 | 90 mg every 8-12 weeks | SC | Effective for ileal strictures [56] | 1b |
| Guselkumab | Anti-IL23p19 | 200-400 mg (Induction) | IV | Rapid molecular response in UC [49] | 1b |
| Upadacitinib | JAK Inhibitor | 15-30 mg daily | Oral | Requires VTE risk assessment [59]C | 4 |
| Filgotinib | JAK Inhibitor | 200 mg daily | Oral | Modulates T-cell gene expression [71]D | 5 |
Supportive Care and Complication Management
- ▸Exclusive Enteral Nutrition (EEN) for 6-8 weeks is the primary induction therapy for pediatric Crohn's disease, offering superior mucosal healing over steroids.
- ▸Intestinal Ultrasound (IUS) is a critical non-invasive tool for monitoring transmural healing and identifying complications like strictures (luminal diameter < 1 cm).
- ▸Chronic management must include proactive screening for anemia, osteoporosis, and trace element deficiencies (Se, Zn, Mg) to prevent long-term morbidity.
The of Inflammatory Bowel Disease (IBD) extends beyond controlling luminal inflammation; it requires a comprehensive approach to address acute complications, chronic nutritional deficiencies, and long-term systemic effects. Effective supportive care integrates advanced imaging, nutritional optimization, and proactive screening for extraintestinal manifestations to improve quality of life and minimize surgical requirements [80]D[83]D.
Step 1: Initial Assessment and Severity Classification
Immediate assessment must distinguish between purely inflammatory activity and structural complications such as strictures, abscesses, or toxic megacolon. Clinicians should utilize Multiparametric Intestinal Ultrasound (MPUS) or Magnetic Resonance Enterography (MRE) to evaluate transmural involvement [74][96]D.
- Criteria for Severity: In pediatric patients, a weighted Paediatric Crohn's Disease Activity Index (wPCDAI) ≤ 12.5 indicates clinical remission, while higher scores necessitate aggressive intervention [75].
- Imaging Thresholds: A bowel wall thickness (BWT) > 3 mm on IUS is a key indicator of activity [88]D[96]D. For strictures, a luminal diameter < 1 cm with pre-stenotic dilation > 3 cm on CTE or MRE typically defines a significant fibrostenotic lesion [90]D[92]D.
- Disposition: Patients with signs of bowel obstruction, perforation, or toxic megacolon (e.g., colonic diameter > 6 cm) require immediate surgical consultation and inpatient stabilization [80]D.
Step 2: Nutritional Induction and Barrier Preservation
Nutritional therapy is the cornerstone of supportive care, particularly in pediatric (CD). Exclusive Enteral Nutrition (EEN), providing 100% of daily caloric requirements via liquid formula for 6 to 8 weeks, is the gold standard for inducing remission [75][86]D.
Mechanism and Rationale: EEN works by eliminating dietary antigens, modulating the gut microbiota, and enhancing mucosal barrier integrity [82]D[93]. Unlike corticosteroids, EEN promotes superior mucosal healing and avoids growth suppression (Level 1b) [75][85]D. For patients unable to tolerate EEN, the Crohn's Disease Exclusion Diet (CDED) combined with 50% Partial Enteral Nutrition (PEN) offers a more palatable alternative that maintains similar efficacy in microbiome modulation [95]. In the postoperative setting, EEN should be administered for ≥ 2 months to reduce the risk of endoscopic recurrence (defined as a Rutgeerts score ≥ i2) [76].
Step 3: Management of Chronic Systemic Complications
Chronic IBD management must address anemia, bone loss, and trace element deficiencies which often persist despite clinical remission.
- Anemia and Thrombosis: Anemia is the most common systemic complication, driven by iron deficiency and chronic inflammation [87]D. Intravenous Iron (e.g., Ferric Carboxymaltose 1000 mg) is preferred over oral iron in active disease to avoid irritation and poor absorption [87]D. Prophylactic anticoagulation should be considered during flares due to the high risk of thromboembolism [87]D.
- Bone Health: Prolonged corticosteroid use significantly reduces bone mineral density (BMD) [77]. Patients on steroids should receive Calcium 1000–1200 mg/day and Vitamin D 800–1000 IU/day [77].
- Trace Elements: Deficiencies in Selenium, Zinc, and Magnesium exacerbate oxidative stress and impair epithelial repair [79]D. Selenium supplementation (50–200 μg/day) may alleviate inflammation by regulating macrophage polarization [79]D.
Step 4: Management of Fibrostenosing Disease
Strictures occur in approximately 30% of CD patients and require a multimodal approach to avoid resection [56][92]D.
- Medical Management: Ustekinumab (6 mg/kg IV induction, then 90 mg SC every 8 weeks) has shown efficacy in symptomatic ileal strictures, potentially reducing the need for surgery [56].
- Endoscopic Intervention: For short (< 4–5 cm), accessible strictures, Endoscopic Balloon Dilation (EBD) or Endoscopic Stricturotomy (ESt) are first-line [84]D[94]. ESt achieves symptomatic improvement in 64.2% of patients and is particularly useful for refractory anastomotic strictures [94].
Step 5: Long-term Surveillance and Resolution Criteria
Resolution is no longer defined by symptoms alone but by transmural healing [89]D.
- Monitoring: IUS should be performed every 3–6 months to monitor BWT and vascularity (via Color Doppler) [74][96]D.
- Cancer Surveillance: Patients with Ulcerative Colitis or Crohn's colitis require surveillance starting 8 years after diagnosis [78]D. High-definition chromoendoscopy is the preferred technique to detect flat, indistinct dysplastic lesions [78]D[84]D.
- Fatigue Management: Fatigue affects 50% of patients and must be addressed by screening for anemia, vitamin D deficiency, and psychological distress, even when the disease is quiescent [83]D.
| Intervention | Dose/Protocol | Indication | Evidence Level |
|---|---|---|---|
| Exclusive Enteral Nutrition (EEN) | 100% of calories via formula for 6–8 weeks | Induction of remission in pediatric CD | 1b [75][86]D |
| Postoperative EEN | Exclusive formula for ≥ 2 months | Prevention of recurrence after resection | 1b [76] |
| Ustekinumab | 6 mg/kg IV (load), then 90 mg SC q8w | Symptomatic ileal stricturing CD | 2b [56] |
| Intravenous Iron | 1000 mg (e.g., Ferric Carboxymaltose) | IBD-associated iron deficiency anemia | 5 [87]D |
| Calcium/Vitamin D | 1200 mg Ca / 800-1000 IU Vit D daily | Prevention of steroid-induced bone loss | 2a [77] |
| Step | Clinical Scenario | Action | Rationale |
|---|---|---|---|
| 1 | Failure of EEN to induce remission | Transition to Biologics (e.g., Anti-TNF) | Inadequate nutritional response requires rapid immunosuppression [82]D |
| 2 | Symptomatic stricture > 5 cm | Surgical Resection | Long strictures are less responsive to EBD/ESt and carry perforation risk [92]D[94] |
| 3 | Refractory Fatigue (Normal Labs) | Psychosocial/Sleep Assessment | Fatigue in IBD is multifactorial and persists despite biochemical remission [83]D |
| 4 | Dysplasia on Surveillance | Advanced Endoscopic Resection or Colectomy | High risk of progression to colorectal cancer [78]D[84]D |
Special Populations
- ▸Maintenance of remission is the most critical factor for successful pregnancy outcomes in IBD patients.
- ▸Pediatric IBD requires aggressive monitoring for growth failure and a standardized protocol for acute severe colitis.
- ▸Elderly patients require strict steroid-sparing strategies due to heightened risks of infection and metabolic complications.
The of Inflammatory Bowel Disease (IBD) requires significant modification when applied to special populations, including pregnant individuals, children, and the elderly. These groups often present with unique physiological challenges, altered drug pharmacokinetics, and distinct diagnostic requirements that necessitate a personalized, multidisciplinary approach [97][113]D.
Pregnancy and Lactation
The primary goal of managing IBD during pregnancy is the maintenance of clinical and histological remission, as active disease at the time of conception or during gestation is the strongest predictor of adverse maternal and fetal outcomes [101][113]D. Active IBD increases the risk of preterm birth, which is associated with long-term offspring morbidities such as epilepsy, asthma, and autism [107].
Diagnostic and Monitoring Modifications
Monitoring disease activity during pregnancy must prioritize non-invasive tools. Fecal calprotectin remains a reliable biomarker for assessing mucosal inflammation [108]D. While endoscopy is generally avoided, transperineal ultrasound (TPUS) has emerged as a practical, non-invasive alternative to sigmoidoscopy for evaluating rectal wall thickness and vascularity [112]D. TPUS offers high diagnostic accuracy for detecting perianal complications without the risks associated with sedation or bowel preparation [112]D.
Therapeutic Safety and Protocols
Most maintenance therapies are continued throughout pregnancy to prevent flares. Anti-TNF agents (e.g., infliximab, adalimumab) have well-established safety profiles [103]. Newer advanced therapies, including vedolizumab and ustekinumab, also demonstrate favorable safety. A meta-analysis of 17,441 pregnancies found a pooled prevalence of early pregnancy loss of 8.2% and preterm birth of 8.9% among those on advanced therapies, which is comparable to the general IBD population [22].
- Vedolizumab: Safe for use; studies show no significant increase in congenital malformations or small-for-gestational-age (SGA) infants compared to other biologics [102].
- Ustekinumab: Safety is comparable to anti-TNF therapy regarding live births and major congenital anomalies [103].
- Corticosteroids: While used for flares, they should be minimized due to risks of gestational diabetes and neonatal adrenal suppression [115]D.
- Thiopurines: Associated with a potential increase in intrahepatic (ICP), which has a pooled prevalence of 1.6% in the IBD population [101].
Delivery and Surgical Considerations
Mode of delivery is primarily determined by obstetric indications, except in cases of active perianal Crohn's disease where a Cesarean section is preferred to avoid sphincter injury [100]. Women with prior abdominal surgery, particularly open procedures for Crohn's disease, face a higher risk of adverse birth outcomes compared to those who underwent laparoscopic interventions [104].
Pediatric-Onset IBD
Pediatric IBD (pIBD) is characterized by a more extensive and aggressive phenotype than adult-onset disease, with a higher prevalence of pan-colitis and rapid disease progression [111]D.
Growth and Development
Growth failure is a hallmark of pIBD, resulting from chronic inflammation, malnutrition, and the growth-suppressing effects of corticosteroids [111]D. Management must prioritize steroid-sparing strategies and nutritional optimization. Exclusive Enteral Nutrition (EEN) is often used as first-line therapy for inducing remission in pediatric Crohn's disease to avoid steroid toxicity [114]D.
Acute Severe Colitis (ASC) Protocol
Pediatric ASC is a medical emergency requiring a standardized, proactive approach [98].
- Step 1: Admit for intensive monitoring and initiate IV methylprednisolone 1-1.5 mg/kg/day (maximum 60 mg/day) [98].
- Step 2: Assess response by day 3 using the Pediatric Ulcerative Colitis Activity Index (PUCAI). If PUCAI > 45, consider second-line therapy [98].
- Step 3: Transition to rescue therapy with Infliximab (5-10 mg/kg) or Cyclosporine if steroids fail [98].
Environmental Factors
Passive smoking exposure is a critical modifiable risk factor in children. It significantly increases the incidence of both Crohn's disease and ulcerative colitis and is linked to poorer long-term outcomes [99]. Conversely, early-life factors such as and a diverse maternal diet may exert a protective effect against the development of pIBD [110]D[114]D.
Elderly Patients
Managing IBD in the elderly (typically defined as >60 or 65 years) is complicated by comorbidities, polypharmacy, and an increased susceptibility to medication side effects [115]D.
- Corticosteroid Risks: The elderly are at significantly higher risk for steroid-induced osteoporosis, infections, and neuropsychiatric disturbances. Steroid-sparing regimens are mandatory [115]D.
- Diagnostic Thresholds: Symptoms in the elderly may be subtler or confounded by diverticular disease or ischemic colitis. Biomarkers like fecal calprotectin are essential to differentiate IBD from other age-related pathologies [108]D.
- Treatment Adjustments: While advanced therapies are effective, clinicians must carefully screen for malignancy and latent infections (e.g., tuberculosis) before initiation [100].
| Medication Class | Pregnancy Safety Profile | Clinical Recommendation |
|---|---|---|
| Anti-TNF (Infliximab, Adalimumab) | Well-established safety [103] | Continue through pregnancy; consider timing of last dose. |
| Integrin Inhibitors (Vedolizumab) | Low risk of adverse outcomes [102] | Safe to continue; no increase in congenital anomalies. |
| IL-12/23 Inhibitors (Ustekinumab) | Comparable to anti-TNF [103] | Safe to continue; limited but reassuring data. |
| JAK Inhibitors (Tofacitinib) | Limited human data [22] | Generally avoided; switch to safer alternative preconception. |
| Parameter | Recommendation | Threshold/Dose |
|---|---|---|
| First-line Therapy | IV Methylprednisolone [98] | 1-1.5 mg/kg/day (Max 60 mg) |
| Monitoring Tool | PUCAI Score [98] | Assess at Day 3 and Day 5 |
| Failure Threshold | PUCAI > 65 at Day 3-5 | Initiate Rescue Therapy (Infliximab) |
| Surgical Consult | Early involvement [98] | Required upon admission for ASC |
References
- [1]
Phillips J, Tambakis G, Kumar R et al.. “Understanding heterogeneity in the pathogenesis and drug responses of ulcerative colitis through single-cell and spatial transcriptomics.” Frontiers in immunology (2026). PMID: 41988199 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [2]
Lim CT, Pruijt M, Lim GH et al.. “Transperineal ultrasonography in detecting penetrating perianal disease: a systematic review and meta-analysis.” Journal of Crohn's & colitis (2026). PMID: 41873840 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heilmann RM, Jergens AE, Kathrani A et al.. “ACVIM-endorsed statement: consensus statement and systematic review on guidelines for the diagnosis and treatment of chronic inflammatory enteropathy in dogs.” Journal of veterinary internal medicine (2026). PMID: 41742497 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Pelly T, Anand E, Holubar S et al.. “Systematic review: The management of unhealed wounds and persistent perineal sinuses following proctectomy in inflammatory bowel disease.” Techniques in coloproctology (2025). PMID: 41359092 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Al-Shbailat SA, Alqato S, Alkhalaileh AY et al.. “Risk Factors and Outcomes of Immunoglobulin A Vasculitis in Patients with Inflammatory Bowel Disease and vice versa: A Systematic Review of the current literature.” Current gastroenterology reports (2026). PMID: 41569327 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Wang Y, Sun X, Chen J et al.. “Associations between oral health problems and inflammatory bowel disease: evidence from prospective cohort study.” Frontiers in immunology (2026). PMID: 41909690 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [7]
Bælum JK, Rosenberg J, Larsen P et al.. “Extended mesenteric resection in Crohn's disease: EXCEED Study Protocol-a blinded multicenter randomized controlled clinical trial (RCT).” Trials (2025). PMID: 41272703 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [8]
Zhang W, Xie H, Ying S et al.. “Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.” Frontiers in immunology (2026). PMID: 41909686 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [9]
Lanier MH, Hoegger MJ, Itani M et al.. “MRI of Perianal Fistulas: Anatomy, Diagnosis, and Perianal Crohn Disease Treatment Monitoring.” Radiographics : a review publication of the Radiological Society of North America, Inc (2026). PMID: 41678368 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [10]
Wu D, Matsuda T, Xie D et al.. “NOD2-Related Multisystem Inflammatory Disorders and Recent Advances.” Current rheumatology reports (2026). PMID: 41678017 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [11]
Solitano V, Peyrin-Biroulet L, Vermeire S et al.. “Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.” Inflammatory bowel diseases (2026). PMID: 41665650 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [12]
Puca P, Coppola G, Parello S et al.. “Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment.” Best practice & research. Clinical gastroenterology (2025). PMID: 41350098 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [13]
Yang L, Jiang Z, Sun Q et al.. “The inflammation-aging axis: Shared and distinct mechanisms in physiological gut aging and IBD-associated accelerated gut aging.” Bioscience trends (2026). PMID: 41260668 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Lewis A, Ulsamer T, Franco L et al.. “Beyond Nutrients: NOVA-Defined Dietary Patterns in Crohn's Disease and Healthy Adults.” Nutrients (2026). PMID: 41978118 ↗
L1bRCTCited in: Definition, Synonyms, and Classification - [15]
Yamamoto T. “Leucine-rich alpha-2 glycoprotein as a blood biomarker in inflammatory bowel disease: clinical implications and future perspectives.” Expert review of gastroenterology & hepatology (2026). PMID: 41636455 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [16]
Zhan XY, Xu R, Hu LZ et al.. “Indigo Naturalis regulates the gut microbiota to increase SCFAs content and improve ulcerative colitis lesions.” Frontiers in cellular and infection microbiology (2026). PMID: 41987898 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [17]
Mahdy AKH, ElAbd H, Prinzensteiner M et al.. “Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.” Journal of Crohn's & colitis (2026). PMID: 41974192 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Liu W, Wang S, Wang G et al.. “Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004-2024).” Frontiers in immunology (2026). PMID: 41953029 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors, Management - [19]
Niyigena E, Hoffert Y, Afif W et al.. “Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.” Journal of Crohn's & colitis (2026). PMID: 41873130 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Management - [20]
Li X, Zhang H, Wang Q et al.. “C-terminal Fragment Generated by HOIL-1 Cleavage Suppresses Inflammatory Responses of Myeloid Cells to Alleviate Colitis.” Theranostics (2026). PMID: 41799187 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Liu J, Sun X, Yuan P et al.. “Clinical response and risk factors of fecal microbiota transplantation in children: a systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 41975112 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [22]
Moraes BF, Leite GAPD, Visentini LM et al.. “Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis.” Journal of Crohn's & colitis (2026). PMID: 41874976 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Management, Special Populations - [23]
Giusto EA, Pinton P, Giorgi C et al.. “Risk of intestinal cancer in Crohn's disease: re-analysis and meta-regression of population-based cohort studies.” Journal of Crohn's & colitis (2026). PMID: 41778611 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [24]
Xu T, Chen Y, Shen Q et al.. “A systematic review and meta-analysis of anxiety and depression in children and adolescents with inflammatory bowel disease: Prevalence and association.” Journal of psychiatric research (2026). PMID: 41687568 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [25]
Wang W, Liu H, Wei W et al.. “Inflammatory bowel disease and the risk of all caused or specific fracture: a meta-epidemiologic study.” Frontiers in endocrinology (2026). PMID: 41685240 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [26]
Shen Y, Jiang Y, Wang Y et al.. “Increased risk of venous thromboembolism in children and teenagers with inflammatory bowel disease: a systematic review and meta-analysis.” PeerJ (2026). PMID: 41940394 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [27]
Kogias D, Kouklakis G, Papadopoulos V. “Hepatitis E Infection in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.” Journal of viral hepatitis (2026). PMID: 41721452 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [28]
Koroma MM, Chan J, Michaux M et al.. “Pooled prevalence of psychological distress and mental health conditions in older adults with inflammatory bowel disease: a protocol for a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 41721426 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [29]
Zhang Q, Xu F, Liu S et al.. “Long-term risk of bowel resection and mortality associated with sleep behaviours and sleep pattern in patients with inflammatory bowel disease: a large-scale prospective cohort study.” Family medicine and community health (2026). PMID: 41760375 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [30]
Kumar S, Plumb A, Mallett S et al.. “Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn's disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study.” Health technology assessment (Winchester, England) (2026). PMID: 41699939 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [31]
Chen J, Li L, Ran Y et al.. “Exposure to outdoor artificial light at night is associated with a higher risk of ulcerative colitis: a prospective cohort study from the UK Biobank.” Frontiers in public health (2026). PMID: 41694500 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [32]
Nardone OM, D'Amico F, Calabrese G et al.. “Risk of avoidant/restrictive food intake disorders in patients with inflammatory bowel disease: a matched cross-sectional case-control study.” Journal of Crohn's & colitis (2026). PMID: 41974193 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [33]
Zhang Q, Gui P, Liu S et al.. “Long-Term Risk of Inflammatory Bowel Disease With Sarcopenia Status: A Large-Scale Prospective Cohort Study.” Geriatrics & gerontology international (2026). PMID: 41932853 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [34]
Yap JM, Wall CL, Meredith-Jones K et al.. “A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease.” Nutrients (2026). PMID: 41829955 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [35]
Xu T, Xie Y. “Clinical characteristics and risk factors analysis of Clostridioides difficile infection in ulcerative colitis patients during biologic therapy.” Frontiers in cellular and infection microbiology (2026). PMID: 41969661 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management - [36]
Fries W, Costantino G, Viola A. “Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern.” Drugs & aging (2026). PMID: 41886038 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [37]
Choi SJ, Choi ES, Kim HY et al.. “Revised Criterion for Identifying Small-Bowel Stricture in Crohn Disease at CT Enterography.” Radiology (2026). PMID: 41874296 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Shen H, Yu X, Wang Z et al.. “Gut Microbiota Remodeling Mediates the Therapeutic Effects of a Plant-Based Medicine on DSS-Induced Ulcerative Colitis in Mice via the Butyrate-SVCT1-Vitamin C Axis.” International journal of molecular sciences (2026). PMID: 41828467 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Lyu W, Zhang Z, Liu L et al.. “Gut microbiota and macrophage crosstalk: implications for colitis-associated colorectal cancer.” Frontiers in cellular and infection microbiology (2026). PMID: 41816358 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [40]
Fouad Y, Aboelela AS. “Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.” World journal of gastroenterology (2026). PMID: 41810448 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Zeng SH, Jiang XY, Lin DR et al.. “Mechanisms and therapeutic potential of traditional Chinese medicine for inflammatory bowel disease.” World journal of gastroenterology (2026). PMID: 41809460 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [42]
Zhao Y, Zhai X, Wang H et al.. “A multi-machine learning framework identifies novel PANoptosis-related biomarkers and their immune landscape in ulcerative colitis: Insights from transcriptomics and experimental validation.” Frontiers in immunology (2026). PMID: 41789070 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [43]
Zou Q, Zhang W, Xie H et al.. “Inflammatory bowel disease through the lens of microbe-host interactions: immunomodulation, metabolic effects, and genetic susceptibility in microbiota dysbiosis.” Frontiers in cellular and infection microbiology (2026). PMID: 41778020 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [44]
Chen L, Hua J. “Identification of Novel Biomarkers for Crohn's Disease Through the Integration of Machine Learning, Colocalization, and SMR Analysis.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41773807 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Bahaa MM, Abdallah MS, Mosalam EM et al.. “Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review.” Inflammopharmacology (2026). PMID: 41770503 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [46]
He Z, Zhang YN, Wei JC et al.. “Increased risk of inflammatory bowel disease in ankylosing spondylitis compared to psoriasis.” Frontiers in immunology (2026). PMID: 41727477 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Kumar S, Sarkar B. “From rodents to chips: preclinical models of inflammatory bowel disease with emphasis on host-microbiome interactions.” American journal of physiology. Gastrointestinal and liver physiology (2026). PMID: 41721794 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [48]
Colombel JF, Danese S, Schreiber S et al.. “Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.” United European gastroenterology journal (2026). PMID: 41986154 ↗
L1bRCTCited in: Management - [49]
Hart A, Sridhar S, Venkat S et al.. “Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis.” BMJ open gastroenterology (2026). PMID: 41871904 ↗
L1bRCTCited in: Management - [50]
De Greef E, Turner D, Kierkuś J et al.. “Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.” Journal of Crohn's & colitis (2026). PMID: 41843763 ↗
L1bRCTCited in: Management - [51]
Oldenburg L, Haanappel AEG, Ali M et al.. “Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 41724174 ↗
L1bRCTCited in: Management - [52]
Randlová K, Marešová P, Režný L et al.. “Cost-effectiveness of treatment and care of patients with gastrointestinal inflammatory diseases: a systematic review.” Journal of medical economics (2026). PMID: 41861399 ↗
L2aSR_OBSCited in: Management - [53]
Dignass A, Narula N, Pratap K et al.. “IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.” Journal of Crohn's & colitis (2026). PMID: 41802119 ↗
L2bTRIAL_NONRANDOMCited in: Management - [54]
Jairath V, Vuyyuru SK, Zou G et al.. “Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.” BMJ open gastroenterology (2026). PMID: 41720589 ↗
L2bTRIAL_NONRANDOMCited in: Management - [55]
Mould DR, Kutschera M, Primas C et al.. “Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease.” World journal of gastroenterology (2026). PMID: 41693973 ↗
L2bTRIAL_NONRANDOMCited in: Management - [56]
El Ouali S, Baker ME, Lu C et al.. “Ustekinumab for ileal stricturing Crohn's disease-an international multicenter retrospective cohort study.” Journal of Crohn's & colitis (2026). PMID: 41934342 ↗
L2bCOHORTCited in: Management, Supportive Care and Complication Management - [57]
Calméjane L, Reenaers C, Gay C et al.. “Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.” United European gastroenterology journal (2026). PMID: 41880233 ↗
L2bCOHORTCited in: Management - [58]
Tímár ÁE, Hernádfői M, Teutsch B et al.. “Association of extraintestinal manifestations and disease severity in paediatric inflammatory bowel disease: a multicentre cohort study.” BMJ open gastroenterology (2026). PMID: 41734978 ↗
L2bCOHORTCited in: Management - [59]
Mo R, Yu S, Xu H et al.. “Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports.” Frontiers in immunology (2026). PMID: 41853288 ↗
L4CASE_REPORTCited in: Management - [60]
Kakiuchi T, Shimada S, Zhang Y et al.. “Case Report: Interleukin-23 blockade achieves sustained remission in Niemann-Pick type C-associated Crohn's disease refractory to anti-tumor necrosis factor therapy.” Frontiers in immunology (2026). PMID: 41798938 ↗
L4CASE_REPORTCited in: Management - [61]
Nitskovich R, Jóźwik A, Sobolewski P et al.. “Bowel-Associated Dermatosis and Arthritis Syndrome (BADAS) - A Literature Review With Diagnostic and Therapeutic Implications and a Report of Two Cases of BADAS Associated With Inflammatory Bowel Disease.” Archivum immunologiae et therapiae experimentalis (2026). PMID: 41722086 ↗
L4CASE_REPORTCited in: Management, Supportive Care and Complication Management - [62]
Li Z, Sun Y, Wu J et al.. “Mesenchymal Stem Cells Derived Extracellular Vesicles in Inflammatory Bowel Disease: Therapeutic Efficacy and Bioengineering Applications.” International journal of nanomedicine (2026). PMID: 41993781 ↗
L5REVIEW_NARRATIVECited in: Management - [63]
Gao J, Liu Y, Xia T et al.. “Mapping the landscape and future directions of stem cell therapy for inflammatory bowel disease.” Stem cell research & therapy (2026). PMID: 41992341 ↗
L5REVIEW_NARRATIVECited in: Management - [64]
Mori M, Nakao YM, Honda M et al.. “COVID-19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database.” Pharmacoepidemiology and drug safety (2026). PMID: 41990848 ↗
L5OTHERCited in: Management - [65]
Raine T, Lewis JD, Parkes GC et al.. “Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.” Journal of Crohn's & colitis (2026). PMID: 41978350 ↗
L5OTHERCited in: Management - [66]
Simpson AN, Sutradhar R, Benchimol EI et al.. “Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study.” Journal of Crohn's & colitis (2026). PMID: 41964942 ↗
L5OTHERCited in: Management - [67]
Dreznik Y, Sharabi S, Shouval D et al.. “Surgically Treated Perianal Abscess in Children: Clinical Characteristics and Subsequent Diagnosis of Crohn's Disease.” European journal of pediatrics (2026). PMID: 41964806 ↗
L5OTHERCited in: Management - [68]
Pérez-Galindo P, Gisbert JP, Carrillo-Palau M et al.. “Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry.” Journal of Crohn's & colitis (2026). PMID: 41886507 ↗
L5OTHERCited in: Management - [69]
Roblin X, Nancey S, Papamichael K et al.. “Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease.” United European gastroenterology journal (2026). PMID: 41880240 ↗
L5OTHERCited in: Management - [70]
Meningher T, Finkel O, Nayshool O et al.. “Transcriptomic profiling of fecal aspirates as a tool for prediction of endoscopic inflammation in small bowel Crohn's disease.” Journal of Crohn's & colitis (2026). PMID: 41879069 ↗
L5OTHERCited in: Management - [71]
Wendt ER, Liang Y, Park G et al.. “Filgotinib treatment modulates frequency and gene expression of circulating immune cell subsets in ulcerative colitis.” Journal of Crohn's & colitis (2026). PMID: 41879068 ↗
L5OTHERCited in: Management - [72]
Hudson AS, Isaac DM, Ma H et al.. “Early intestinal ultrasound findings predict remission and treatment response at 1 year in pediatric Crohn's disease.” Journal of Crohn's & colitis (2026). PMID: 41866919 ↗
L5OTHERCited in: Management - [73]
Zafeiropoulou K, Hageman IL, Mu T et al.. “Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease.” Frontiers in cellular and infection microbiology (2026). PMID: 41859469 ↗
L5OTHERCited in: Management - [74]
Jairath V, Adsul S, Allocca M et al.. “Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.” Inflammatory bowel diseases (2025). PMID: 40971817 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [75]
Pigneur B, Martinez-Vinson C, Bourmaud A et al.. “Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 41570843 ↗
L1bRCTCited in: Supportive Care and Complication Management - [76]
Zhang M, Tu Q, Luo K et al.. “Postoperative exclusive enteral nutrition as a bridging therapy to reduce endoscopic recurrence after intestinal resection in Crohn's disease: A randomized controlled trial.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 41483478 ↗
L1bRCTCited in: Supportive Care and Complication Management - [77]
Li CC, Xu LP, Zheng TT et al.. “The effects of steroid treatment on osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis.” Medicine (2026). PMID: 41560068 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [78]
Shinagawa T, Okada S, Shiratori H et al.. “Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.” International journal of clinical oncology (2026). PMID: 41721152 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [79]
Yan Y, Du R, Xia C et al.. “Nutritional trace elements influence the pathogenesis and resolution of inflammatory bowel disease.” Food & function (2026). PMID: 41685405 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [80]
Wilk A, Pawłowski M, Balcerczak E et al.. “Advances in the Treatment of Ulcerative Colitis-From Conventional Therapies to Targeted Biologics and Small Molecules.” International journal of molecular sciences (2026). PMID: 41683952 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [81]
Baharad Y, Engel T, Ben-Horin S. “Dietary therapy for small bowel Crohn's disease.” Current opinion in gastroenterology (2026). PMID: 41612628 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [82]
Axi L, Wang Y, Meng W. “Research progress on exclusive enteral nutrition combined with biologics in the treatment of adult Crohn's disease.” Journal of Crohn's & colitis (2026). PMID: 41452759 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [83]
Arnim UV, Scholz K. “Fatigue in inflammatory bowel disease.” Best practice & research. Clinical gastroenterology (2025). PMID: 41350094 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [84]
Roseira J, Estevinho MM, Gros B et al.. “Advances in endoscopy in IBD diagnostics and management.” Best practice & research. Clinical gastroenterology (2025). PMID: 41350091 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [85]
Hoffmann NV, Hobbs E, Wershil BK. “Nutritional Therapy in Pediatric Allergic Bowel Disease.” Gastroenterology clinics of North America (2025). PMID: 41238283 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [86]
Masthan A, Strople J, Runde J. “Dietary Therapy in the Management of Inflammatory Bowel Disease: A Lasting Legacy and a New Frontier.” Gastroenterology clinics of North America (2025). PMID: 41238281 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [87]
Tesoi DF, Hancianu M, Trandafir LM et al.. “Thrombosis and Anemia in Pediatric Inflammatory Bowel Disease: Pathophysiology, Clinical Impact and Future Directions.” International journal of molecular sciences (2025). PMID: 41226447 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [88]
Di Vincenzo F, Del Vecchio LE, Covello C et al.. “Beyond the mucosa: The emerging role of endoscopic ultrasound in the diagnosis and management of inflammatory bowel disease.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41188166 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [89]
Eggermont E, Gecse K, Krugliak Cleveland N et al.. “Ulcerative colitis: moving beyond the mucosal dogma.” The lancet. Gastroenterology & hepatology (2026). PMID: 41173014 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [90]
El Sadaney AO, Baker ME, Ream J et al.. “Toward eliminating missed important findings in fibrostenosing Crohn's disease at CT and MR enterography.” Abdominal radiology (New York) (2026). PMID: 41171404 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [91]
Shet SS, Lee RJ, Kakish E et al.. “Patient radiation safety in imaging in Crohn's disease.” The British journal of radiology (2026). PMID: 41160487 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [92]
Hoodeshenas S, Dillman JR, Taylor SA et al.. “Crohn Disease Strictures: Multimodality Imaging to Identify Imaging Biomarkers.” Radiographics : a review publication of the Radiological Society of North America, Inc (2025). PMID: 41100354 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [93]
Marind EC, McCullough F. “Gut Health Responses to Nutritional Interventions in Paediatric Crohn's Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review.” Nutrients (2026). PMID: 41978196 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [94]
Rocchi C, Massidda M, Piroddu J et al.. “Endoscopic Stricturotomy for the Treatment of Inflammatory Bowel Diseases' Ileocolonic Strictures: A Systematic Review.” Journal of gastrointestinal and liver diseases : JGLD (2025). PMID: 41004825 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [95]
Rohani P, Ansari A, Shaygantabar M et al.. “The Effects of the Crohn's Disease Exclusion Diet (CDED) Alone Versus CDED Plus Partial Enteral Nutrition (PEN) on Gut Microbiome Composition in Pediatric CD Patients.” MicrobiologyOpen (2025). PMID: 41133990 ↗
L1bRCTCited in: Supportive Care and Complication Management - [96]
Cataletti G, Gridavilla D, Casella M et al.. “Multiparametric intestinal ultrasound in inflammatory bowel diseases: a narrative review.” Expert review of gastroenterology & hepatology (2026). PMID: 41635930 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [97]
Kucharzik T, Taylor S, Allocca M et al.. “ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1.” Journal of Crohn's & colitis (2025). PMID: 40741688 ↗
L1cGUIDELINECited in: Special Populations - [98]
Assa A, Aloi M, Van Biervliet S et al.. “Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization.” Journal of pediatric gastroenterology and nutrition (2025). PMID: 40528309 ↗
L1cGUIDELINECited in: Special Populations - [99]
Mahajan A, Gupta B, Peterson A et al.. “Passive smoking exposure and incidence and disease outcomes of inflammatory bowel disease: a systematic review and meta-analysis.” Frontiers in public health (2025). PMID: 41235209 ↗
L2aSR_OBSCited in: Special Populations - [100]
Al Awadhi S, Al Hassani A, El Ouali S et al.. “Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.” World journal of gastroenterology (2025). PMID: 41024766 ↗
L2aSR_OBSCited in: Special Populations - [101]
Joudaki S, Oladipupo O, Carbery I et al.. “Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy.” Alimentary pharmacology & therapeutics (2025). PMID: 40114011 ↗
L2aSR_OBSCited in: Special Populations - [102]
Nguyen B, Quon S, Williams AJ et al.. “Safety of Vedolizumab in Pregnancy: An Updated Systematic Review and Comprehensive Meta-analysis.” Journal of clinical gastroenterology (2026). PMID: 41397157 ↗
L2aSR_OBSCited in: Special Populations - [103]
Bardak AE, Saeed H, Teker G et al.. “Comparative safety of ustekinumab versus anti-TNF therapy during pregnancy in patients with inflammatory bowel disease: A systematic review and meta-analysis.” Medicine (2025). PMID: 40958297 ↗
L2aSR_OBSCited in: Special Populations - [104]
Mark-Christensen A, Ebert AC, Poulsen GJ et al.. “Risk of adverse pregnancy and birth outcomes after open versus laparoscopic surgery for inflammatory bowel disease: a nationwide cohort study.” Journal of Crohn's & colitis (2026). PMID: 41437648 ↗
L2bCOHORTCited in: Special Populations - [105]
Azzam N, Almadi M, Alfarhan H et al.. “The Impact of Disease Activity and Medications on Pregnancy and Fetal Outcomes in Women With Inflammatory Bowel Disease: A Cohort Study From the IBD-ME Group.” Journal of gastroenterology and hepatology (2026). PMID: 41239802 ↗
L2bCOHORTCited in: Special Populations - [106]
Mårild K, Söderling J, Stephansson O et al.. “Inflammatory Bowel Disease, Periconceptional Disease Activity, and Risk of Major Congenital Anomalies: A Nationwide Cohort Study.” The American journal of gastroenterology (2025). PMID: 39945675 ↗
L2bCOHORTCited in: Special Populations - [107]
Friedman S, Garvik OS, Nielsen J et al.. “The Consequences of Preterm Birth in the Children of Mothers with Inflammatory Bowel Disease: A Nationwide Cohort Study.” Inflammatory bowel diseases (2025). PMID: 39899387 ↗
L2bCOHORTCited in: Special Populations - [108]
Devi J, Samaan S, Syal G et al.. “Biomarkers for Disease Activity in Inflammatory Bowel Disease.” Gastroenterology clinics of North America (2026). PMID: 41581945 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [109]
Yılmaz M, Gökçe A, Öztürk O. “What Is the Real Impact of Smoking on Diseases Alleged to Benefit from It?” European addiction research (2025). PMID: 41129423 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [110]
Ribeiro-Mourão F, Agrawal M, Torres J et al.. “Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact?” Inflammatory bowel diseases (2025). PMID: 41078161 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [111]
Al-Beltagi M, Saeed NK, Mani PKC et al.. “Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers.” World journal of gastroenterology (2025). PMID: 41024758 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [112]
Pal P, Mateen MA, Pooja K et al.. “Transperineal ultrasound: Role in inflammatory bowel disease management.” World journal of gastroenterology (2025). PMID: 40933455 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [113]
Freitas Queiroz NS, Furfaro F. “Pregnancy and IBD: A practical guide for physicians.” Best practice & research. Clinical gastroenterology (2025). PMID: 40769612 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [114]
Kuk N, Yao CK, Srinivasan AR et al.. “Nutrition in inflammatory bowel disease: new trends.” Current opinion in clinical nutrition and metabolic care (2025). PMID: 40657733 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [115]
Feuerstein JD, Rubin DT, Aberra FN et al.. “Appropriate Use and Complications of Corticosteroids in Inflammatory Bowel Disease: A Comprehensive Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40588110 ↗
L5REVIEW_NARRATIVECited in: Special Populations